ICICI Securities has issued differentiated recommendations across five stocks following their Q1 FY27 earnings. The brokerage maintains a Buy rating on Fortis Healthcare and Hindalco Industries, an Add rating on Titan Company and Blue Star, and a Hold rating on Ramco Cements. According to the report, the potential upside ranges from around 1% to 17% based on report prices. However, recent developments show mixed signals from other brokerages - Morgan Stanley maintains Overweight rating on Titan Company with a target price of ₹5,483, while Elara Capital downgraded the stock to Accumulate with a target price of ₹5,300. Citi also maintains a Buy rating with a higher target price of ₹5,700. Notably, ICICI Securities has raised the target price of SBI to ₹1,300 from ₹1,250, maintaining its Buy rating on the banking major.
The June-quarter earnings picture presented mixed results across the five companies. Hindalco reported a sharp earnings surge driven by stronger aluminium realisations, with Q1 EBITDA beating estimates by 29% at ₹140 billion, while Fortis Healthcare continued to benefit from hospital expansion initiatives. Titan Company demonstrated strong jewellery growth with jewellery revenue growing 38% excluding bullion despite gold price volatility, though management noted some softness in plain gold jewellery emerged in late July. Blue Star faced significant pressure on margins due to a delayed summer season and elevated input costs, according to the report.
Ramco Cements managed to beat brokerage estimates but continues to navigate industry headwinds and cost pressures that impact operational performance. The company's ability to outperform expectations despite challenging market conditions demonstrates resilience in the cement sector.
In the banking sector, SBI emerged as a standout performer with strong Q1 results that exceeded expectations. The bank's Q1FY27 PAT of ₹211 billion was up 10% YoY and beat estimates by 4%, led by NII growth of 14% YoY and stable net slippages. The bank sustained 1.1% RoA in a seasonally weak quarter, with core PPOP growth strong at 20% YoY. Kotak Mahindra Bank also showed resilience with NIM improving 5bps QoQ to 2.86%, while Axis Bank maintained its Buy rating with a raised target price of ₹1,310 from ₹1,180.
The latest brokerage recommendations reflect a cautiously optimistic outlook across sectors, with ICICI Securities maintaining its Buy rating on Hindalco Industries and Fortis Healthcare while raising target prices. The mixed signals from other brokerages highlight the varied performance across sectors, with Titan Company receiving conflicting recommendations despite strong jewellery growth. Market analysts continue to monitor execution capabilities and margin sustainability across all five companies as they navigate different sector challenges and growth opportunities. ICICI Securities' bullish stance on SBI is supported by the bank's strong Q1 performance and positive medium-term growth initiatives including setting up a collection vertical for the non-salaried segment and raising BRE limits to ₹100 million for SME.
